Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Despite two cases of remission, effective HIV cure is still years away

Following the news of a UK patient (The London Patient) who has been in remission with undetectable levels of HIV viral load for 18 months, becoming the second patient who has experienced disease free remission from HIV, Patrick Aiyes, MEng, Immunology Analyst at GlobalData, a leading data and analytics company comments: “The London Patient, similar […]
Read more

Tecentriq assumes pole position with FDA approval but Keytruda looms in triple negative breast cancer

On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). Adam Pearson, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his view […]
Read more

Roche’s acquisition of Spark Therapeutics is a long-term investment in the hemophilia A gene therapy market

Following the news (25 February 2019) that Roche has entered into a definitive merger agreement to fully acquire Spark Therapeutics for $4.3bn, Tajekesa Chapman, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the acquisition: “The hemophilia market is currently undergoing major changes in its treatment landscape due to advances […]
Read more

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors

Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combination with Pfizer’s Inlyta, a tyrosine kinase inhibitor, can significantly improve clinical outcomes for renal cancer patients. Amrita Gujral, Pharma Analyst at GlobalData, a leading data and analytics company, offers her […]
Read more

Commercial prospects for immuno-oncology development across oncology indications in untapped cancer types or in combinations, says GlobalData

Immuno-Oncology (IO) development is booming across the 8MM*, with IO agents being investigated in most cancer types, in combination or alone, representing a huge commercial opportunity for established players and novel developers alike, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Immuno-oncology Development Trends and Opportunities’ combines research with a global, cross-specialty […]
Read more

APAC drug delivery devices market to reach $5.4 billion in 2023

Asia Pacific (APAC) region contributed 21% of global revenue in 2016 and the region is expected to witness higher growth compared to other regions. The company’s latest reveals that Japan will emerge as the major country in APAC region contributing 64% of the revenue in 2023. Japan contributed 62% of the revenue in the region […]
Read more
1 … 106 107 108